VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance

The Hematopoietic Cell-Specific Rho GTPase Inhibitor ARHGDIB/D4GDI Limits HIV Type 1 Replication

(2011) Tadashi Watanabe et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression

(2011) Hee Jun Cho et al.   CANCER LETTERS

LyGDI, a Novel SHIP-Interacting Protein, Is a Negative Regulator of FcγR-Mediated Phagocytosis

(2011) Payal Mehta et al.   PLoS One

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Rho GDP Dissociation Inhibitor 2 Suppresses Metastasis via Unconventional Regulation of RhoGTPases

(2009) K. Moissoglu et al.   CANCER RESEARCH

RhoGDI2 Expression Is Associated with Tumor Growth and Malignant Progression of Gastric Cancer

(2009) H. J. Cho et al.   CLINICAL CANCER RESEARCH

RhoGDI2 as a therapeutic target in cancer

(2009) Hee Jun Cho et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Silencing of D4-GDI Inhibits Growth and Invasive Behavior in MDA-MB-231 Cells by Activation of Rac-dependent p38 and JNK Signaling

(2009) Yaqin Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

(2008) M A Kim et al.   HISTOPATHOLOGY